Skip to main content
    C

    CareDx Inc (CDNA)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $74.56
    +0.84 (+1.14%)

    Market Cap: $4.09B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    CareDx Inc (CDNA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    CareDx (CDNA) has a market cap of $4.09B and an enterprise value of $3.72B. Revenue grew 73.12% over the last 12 months from the 12 months before. Its share count is down 5.22% from a year earlier.

    Total Valuation

    Enterprise value is 9.13% below the market cap, as cash exceeds debt.

    Market Cap$4.09B
    Enterprise Value$3.72B
    Latest price (Nov 17, 2026)$74.56

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.62% in the quarter ended Jun 30, 2026 and shrank 0.70% a year over 2 years.

    Shares Outstanding51.47M
    Shares Change (YoY)-5.22%
    Shares Change (QoQ)+0.62%
    Share Count Growth (2Y CAGR)-0.70%

    Valuation Ratios

    Sales and book value multiples are 6.5x and 9.0x. Its year-end P/E ranged from 31.4x to 905.6x from 2020 to 2025.

    P/E Ratio48.7x
    Forward P/E41.0x
    P/S Ratio6.5x
    Forward P/S7.8x
    P/B Ratio9.0x
    P/TBV Ratio10.3x
    P/FCF Ratio45.3x
    P/OCF Ratio43.7x
    PEG Ratio1.1

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 26.5x EBITDA and 40.9x free cash flow.

    EV / Earnings33.5x
    EV / Sales6.3x
    EV / EBITDA26.5x
    EV / FCF40.9x

    Price Statistics

    The stock is up 367.90% over 52 weeks and trades 10.82% above its 50-day average.

    Beta (1Y)1.29
    52-Week Change+367.90%
    1-Month Change+11.15%
    3-Month Change+60.31%
    6-Month Change+263.18%
    5-Year Change+71.39%
    10-Year Change+2294.79%
    Total Return (1Y)+367.90%
    Total Return (3Y CAGR)+98.49%
    Total Return (5Y CAGR)+11.07%
    Return vs SPY (1Y)+361.54%
    Max Drawdown (1Y)-23.64%
    Max Drawdown (3Y)-65.96%
    Sharpe Ratio (1Y)2.21
    Correlation with SPY (1Y)0.25
    50-Day Average$67.28
    200-Day Average$37.24
    52-Week Range$15.56 to $90.87
    RSI (14 Days)50.2
    Average Volume (20 Days)1.30M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.58x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.58x
    Quick Ratio4.51x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 26.08% over the last 12 months, against a 5-year average of -18.07%.

    Return on Equity (ROE)26.08%
    Return on Assets (ROA)20.83%
    ROE (5Y Average)-18.07%
    ROA (5Y Average)-10.95%
    ROIC (5Y Average)-9.98%
    Asset Turnover1.21x
    Inventory Turnover8.07x
    Receivables Turnover14.94x
    Cash Conversion Cycle45 days

    Taxes

    Income tax took 3.63% of pretax income over the last 12 months.

    Income Tax (TTM)$4.18M
    Effective Tax Rate3.63%

    Scores

    CDNA has an Altman Z-Score of 22.65, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score22.65
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $590.04M over the last 12 months.

    Revenue$590.04M
    Revenue Growth (YoY)+73.12%
    Gross Profit$455.28M
    Operating Income$108.14M
    Pretax Income$115.19M
    Net Income$111.01M
    EBITDA$130.73M
    Reported EPS (TTM)$1.53

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.85% of the $532.99M in total assets.

    Cash and Equivalents$373.64M
    Total Debt$0
    Net Cash$373.64M
    Net Cash Per Share$7.26
    Working Capital$335.52M
    Shareholder Equity$425.60M
    Book Value Per Share$8.27
    Tangible Book Value$371.07M
    Tangible Book Per Share$7.21
    Total Assets$532.99M
    Total Liabilities$107.39M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $8.95M of capital spending, operating cash flow left $84.70M of free cash flow.

    Operating Cash Flow$93.66M
    Capital Expenditures$8.95M
    Free Cash Flow$84.70M
    FCF Per Share$1.64
    Depreciation and Amortization$21.91M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 18.33%, against a 5-year average of -20.49%.

    Gross Margin77.16%
    Operating Margin18.33%
    Pretax Margin19.52%
    Net Margin18.81%
    EBITDA Margin22.16%
    FCF Margin14.36%
    Gross Margin (5Y Average)66.11%
    Operating Margin (5Y Average)-20.49%
    Net Margin (5Y Average)-18.38%

    Growth

    Revenue grew 5.68% a year over 3 years.

    Revenue Growth (3Y CAGR)+5.68%
    Revenue Growth (5Y CAGR)+14.59%
    EPS Growth (5Y CAGR)+49.63%
    FCF Growth (5Y CAGR)+6.53%
    Book Value Per Share Growth (2Y CAGR)+9.37%
    Tangible Book Per Share Growth (2Y CAGR)+16.53%

    Revenue and profit by year

    Dividends and Yields

    CDNA does not pay a dividend. Its free cash flow yield is 2.21%.

    Earnings Yield2.05%
    FCF Yield2.21%
    Buyback Yield0.92%
    Shareholder Yield0.92%

    Peer Position

    Against 7 similar companies, CDNA has the 3rd highest P/E.

    P/E Ratio48.7x vs 20.5x median
    P/S Ratio6.5x vs 3.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+73.12% vs +10.43% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 22.72% and EPS growth at 61.47% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+22.72%
    EPS Growth Forecast (2Y CAGR)+61.47%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CDNA

    What is CDNA's market cap?

    CareDx has a market cap of $4.09B. Its enterprise value, which adds debt and subtracts cash, is $3.72B.

    What is CDNA's P/E ratio?

    CareDx has a trailing P/E ratio of 48.7x and a forward P/E of 41.0x.

    How many shares of CDNA are outstanding?

    CareDx has 51.47M shares outstanding. The count is down 5.22% from a year earlier.

    Does CDNA pay a dividend?

    No. CareDx does not pay a dividend.

    How much debt does CDNA have?

    CareDx has $0 of total debt and $373.64M of cash and equivalents, a net cash position of $373.64M.